Actualización en el tratamiento del hipoparatiroidismo posquirúrgico

  1. Ventosa-Viña, Marta 1
  2. Cuéllar-Olmedo, Luis 1
  3. Crespo-Soto, Cristina 1
  4. Palacio-Mures, José María 1
  5. García-Duque, María 1
  6. Lázaro-Martín, Lucía 1
  1. 1 Hospital Universitario Río Hortega. Servicio de Endocrinología. Valladolid. España
Journal:
Revista ORL

ISSN: 2444-7986,  2444-7986

Year of publication: 2022

Volume: 13

Issue: 3

Pages: 239-246

Type: Article

DOI: 10.14201/ORL.27528 DIALNET GOOGLE SCHOLAR lock_openDialnet editor

More publications in: Revista ORL

Sustainable development goals

Abstract

Introduction and objective: Surgical hypoparathyroidism is a common complication following thyroid and parathyroid surgery. It has significant consequences for health and quality of life. The objective of this review is to provide an overview of its prevention, early detection and treatment. Synthesis: Acute hypoparathyroidism can occur after thyroidectomy and parathyroidectomy, especially in high risk patients. Measurement of early postoperative intact parathyroid hormone (PTHi) can help guide patient management. A postoperative PTHi < 10-15 pg/ml combined with serum calcium assay testing 24 hours after surgery yielded the highest diagnostic accuracy for predicting acute hypocalcemia. Permanent hypoparathyroidism is associated with long-term morbidity and poor quality of life, and should be prevented whenever possible.  Conventional treatment consist of oral calcium and active vitamin D analogs. For more severe or symptomatic hypocalcemia it is necessary intravenous calcium. Treatment require monitoring and patient education to avoid wide swings in serum calcium.  However, with standard therapy, maintaining an adequate control often presents a therapeutic challenge.  Recombinant human parathyroid hormone (rhPTH) replacement can lower the doses of calcium and active vitamin D analogs required, while maintaining serum calcium and phosphate  levels within the recommended therapeutic ranges.  It may improve bone metabolism and quality of life on the long term. Additional data on safety and efficacy are needed. Conclusions: Postoperative hypoparathyroidism is common. It requires early diagnosis, pharmacologic intervention and patient education to achieve optimal control and lower the risk of long-term complications. rhPTH seems to be an effective option for those patients who do not  stably mantein their calcium in the target range.  

Bibliographic References

  • Edafe O, Antakia R, Laskar N, Uttley LI, Balasubramanian SP. Systematic review and meta-analysis of predictors of post-thyroidectomy hipocalcemia. Br J Surg. 2014; 101:307-320.
  • Huguet I, Muñoz M, Cortés M, Romero M, Varsavsky M, Gómez J. Protocolo de diagnóstico y manejo de hipocalcemia en postoperatorio de tiroides. Rev Osteoporos Metab Miner. 2020; 12 (2): 71-76.
  • Karakas E, Osei-Agyemang T, Schlosser K, Hoffmann S, Zielke A., Rothmund M et al. The impact of parathyroid auto transplantation during bilateral surgery for Graves disease on postoperative hypocalcemia. Endcor Regul 2008; 42:39-44.
  • Lara H, Fernández S, Gil-Carcedo E, Cuéllar LA, Mayo A, Vallejo LA. Hormona paratiroidea intacta como predictor temprano de hipocalcemia en la tiroidectomía total. Rev. ORL 2016; 7, Supl. 1: 1-42.
  • Shah M, Bancos I, Thompson GB, Richards ML, Kasperbauer JL, Clarke BL et al. Teriparatide therapy and reduced postoperative hospitalization for postsurgical Hypoparathyroidism. JAMA Otolaryngol Neck Surg. 2015; 141(9): 822-7.
  • Orloff LA, Wiseman SM, Bernet VJ, Fahey III TJ, Shaha AR, Shindo ML et al. American Thyroid Association statement on postoperative hypoparathyroidism: diagnosis, prevention and management in adults, Thyroid. 2018; 28 (7): 830-841.
  • Brandi ML, Bilezikian JP, Shoack D, Bouillon R, Clarke BL, Thakker RV et al. Management of hypoparathyroidism: summary statement and guidelines. J Clin Endocrinol Metab. 2016; 101 (6): 2273-2283.
  • Bollerslev J, Rejnmark K, Marcocci C, Shoback DM, Sitges-Serra A, van Biesen W et al. European Society of Endocrinology Clinical Guideline: Treatment of chronic hypoparathyroidism in adults. Eur J Endocrinol.2015; 173: G1-G20.
  • Winer KK, Zhang B, Shrader JA, Peterson D, Smith M, Albert PS et al.Synthetic human parathyroid hormone 1-34 replacement therapy: a randomized crossover trial comparing pump versus injections in the treatment of chornic hypoparathyroidism. J Clin Endocrinol Metab 2012; 97: 391-399.
  • Mannstadt M, Clarke BL, Vokes T, Brandi ML, Ranganath L, Fraser WD, et al. Efficacy and safety of recombinant human parathyroid hormone (1-84) in hypoparathyroidism (REPLACE): a double-blind, placebo-controlled, randomised, phase 3 study. Lancet Diabetes Endocrinol. 2013; 1 : 275-283.
  • Rubin MR, Cusano NE, Fan WW, Delgado Y, Zhang C, Costa AG et al. Therapy of Hypoparathyroidism With PTH (1–84): A Prospective Six Year Investigation of Efficacy and Safety. J Clin Endocrinol Metab 2016;101(7):2742–2750.
  • Tabacco G, Tay ID, Cusano NE, Williams J, Omeragic B, Majeed R et al. Quality of Life in Hypoparathyroidism Improves With rhPTH(1-84) Throughout 8 Years of Therapy. J Clin Endocrinol Metab 2019;104(7):2748–2756.
  • Tay YD, Tabacco G, Cusano NE, Williams J, Omeragic B, Majeed R et al. Therapy or hypoparathyroidism with rh PTH (1-84): a prospective, 8 year investigation of efficacy and safety. J Clin Endocrinol Metab 2019; 104: 5601-5610.
  • Khan AA, Koch CA, Van Uum S, Baillargeon JP, Bollersiev J, Brandi ML et al. Standards of care for hypoparathyroidism in adults: a Canadian and international consensus, Eur J Endocrinol. 2019; 180: 1-23.
  • Castro A, Oleaga A, Parente P, Paja M, Gil Carcedo E, Álvarez Escolá C. Resumen ejecutivo del documento de consenso SEORL CCC-SEEN sobre hipoparatiroidismo postiroidectomía. Endocrinol Diabetes Nutr. 2019; 66(7):459-463.
  • Kazaure HS, Sosa JA. Surgical Hypoparathyroidism. Endocrinol Metab Clin N Am. 2018; 47:783-796.
Data source: Dialnet